ADC Therapeutics (ADCT) Inventory (2021 - 2026)

ADC Therapeutics (ADCT) has reported Inventory for 6 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.

• Quarterly Inventory fell 72.63% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 72.63% YoY) and the FY2025 annual result came in at $4.2 million, up 85.87% from the prior year.
• Inventory climbed to $4.8 million in Q1 2026 per ADCT's latest filing, from $4.2 million in the prior quarter.
• Over the last five years, Inventory for ADCT reached as high as $22.7 million in Q3 2023 and fell as low as $2.3 million in Q4 2024.
• A 5-year average of $14.3 million and a median of $16.0 million in 2024 frame the typical range for Inventory.
• Annual changes were most pronounced in 2022 — Inventory soared 96.62% — and 2024, when it sank 86.09%.
• Year by year, Inventory stood at $12.1 million in 2022, then soared by 33.99% to $16.2 million in 2023, then slumped by 86.09% to $2.3 million in 2024, then soared by 85.87% to $4.2 million in 2025, then advanced by 14.15% to $4.8 million in 2026.
• According to Business Quant data, Inventory over the past three periods registered $4.8 million, $4.2 million, and $18.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.